| Market Cap | ₹59,329 CrMid-range Performer |
|---|---|
| TTM Revenue | ₹17,414 CrOperating Revenue |
| P/E Ratio | 131.2xSector 43.7x |
| 1Yr Change | -10.31%Price Performance |
Key highlights
- FDA approval granted for Pebrilzo (pertuzumab-qcay) injection for HER2-positive breast cancer
- Product serves as a biosimilar to the reference biologic Perjeta (pertuzumab)
- Global settlement with Genentech secures a U.S. launch date in Q3 of calendar year 2028
- Approval marks Biocon's fifth oncology biosimilar to receive regulatory clearance in the U.S.
- Previously received positive CHMP opinion in Europe for marketing authorization in September 2026
Biocon Expands US Oncology Presence with Pebrilzo Approval
Biocon Limited has achieved a regulatory milestone with the U.S. Food and Drug Administration's approval of Pebrilzo, a monoclonal antibody designed to treat HER2-positive breast cancer. The drug works by blocking HER2 receptors on cancer cells, providing a biosimilar alternative to the established reference product Perjeta.
This approval is supported by a comprehensive analytical and clinical data package demonstrating no clinically meaningful differences in safety, quality, or efficacy between the biosimilar and the reference biologic. The addition of Pebrilzo reinforces the company's anti-cancer portfolio, targeting a disease that affects approximately 320,000 women diagnosed with breast cancer annually in the United States.
Settlement with Genentech Defines Commercial Launch Timeline
While the FDA has granted regulatory clearance, the commercialization of Pebrilzo in the United States is governed by a global settlement and license agreement with Genentech. Under this agreement, Biocon has secured an earliest licensed launch window for the third quarter of calendar year 2028. This follows earlier international progress, including a patent settlement announced in October 2026 that allows for a much earlier launch in Europe and the United Kingdom by the first quarter of 2027.
Additionally, the company previously secured a ten-year partnership in Brazil for the same molecule valued at approximately 400 million US dollars, with supplies expected to commence in the fourth quarter of fiscal year 2027.
Financial Performance and Strategic Pipeline Growth
The regulatory milestone comes as Biocon navigates a challenging financial period. For the quarter ended September 30, 2026, the company reported operating revenue of 4,388.9 crore, representing a modest 2.2 percent growth over the previous year. However, net profit for the quarter declined by 51.1 percent year-on-year to 41.3 crore.
Despite current volatility, management has guided for accelerated revenue and profitability in the second half of fiscal 2027. The company's oncology strategy remains focused on long-term growth, with a pipeline that includes proposed biosimilars for nivolumab and pembrolizumab, alongside existing approved products like Ogivri and Fulphila.
Biocon Oncology Portfolio and Pipeline Highlights
- Ogivri (trastuzumab-dkst) for HER2-directed therapy
- Jobevne (bevacizumab-nwgd) for various cancer indications
- Fulphila (pegfilgrastim-jmdb) for neutropenia management
- Aukelso (denosumab-kyqq) recently added to the oncology list
- Proposed biosimilars to trastuzumab/hyaluronidase in development
- Immuno-oncology pipeline focusing on nivolumab and pembrolizumab
Executive Perspective on Biosimilar Access
The U.S. FDA approval of PEBRILZO, our biosimilar pertuzumab, marks another significant milestone in Biocon’s journey to expand access to high-quality biosimilars. As our fifth oncology biosimilar to receive U.S. FDA approval, PEBRILZO strengthens our anti-cancer portfolio and advances our commitment to expanding access to high-quality, affordable biologic medicines.
| Date | Announcement | Amount |
|---|---|---|
| 25 Sep 2026 | UK MHRA approval for new drug product fill-finish unit for Semglee (insulin glargine) at Malaysia facilitySource: biocon.com | – |
| 25 Aug 2026 | Japan MHLW marketing approval for Pegfilgrastim biosimilarSource: biocon.com | – |
| 18 Aug 2026 | US FDA supplemental approval for Yesintek (ustekinumab-kfce) single-dose prefilled autoinjectorSource: biocon.com | – |
| 29 Jul 2026 | Health Canada approval for Yesintek (ustekinumab) autoinjector penSource: biocon.com | – |
| 16 Jul 2026 | European Medicines Agency (EMA) approval for new drug product fill-finish unit for insulins at Malaysia facilitySource: biocon.com | – |
| 11 May 2026 | Health Canada approval for Micafungin for Injection USP (50 mg and 100 mg)Source: biocon.com | – |
What to watch next
- Earliest licensed launch of Pebrilzo in Europe and UK in Q1 CY 2027
- Scheduled announcement of Q3 FY27 quarterly financial results on February 4, 2027
- Commencement of pertuzumab supplies in Brazil starting Q4 FY27
- Planned commercial launch of Pebrilzo in the United States in Q3 2028
| Share price | ₹364.05 |
|---|---|
| Market capitalisation | ₹59,329.01 Cr |
| Revenue (annual) | ₹16,927.00 Cr |
| Net profit (annual) | ₹385.60 Cr |
| Revenue (latest quarter) | ₹4,388.90 Cr+1.22% vs previous quarter |
| Net profit (latest quarter) | ₹41.30 Cr-70.73% vs previous quarter |
| P/E (TTM) | 131.23×Sector 43.74× |
| Promoter holding | 44.68%0.00% QoQ |
| FII holding | 8.64%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Biocon Limited announcing US FDA approval for Pebrilzo biosimilar. Market figures from a third-party data provider.






